Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Go back to Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 47.84 -0.42 (0.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $48.26 | 52 Week High | $77.12 | |||
| Open | $48.44 | 52 Week Low | $49.03 | |||
| Day High | $48.55 | P/E | 31.06 | |||
| Day Low | $47.70 | EPS | $1.54 | |||
| Volume | 11,762,470 | |||||
| Exelixis, Inc. (NASDAQ: EXEL) | Delayed: 22.87 +0.05 (0.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.82 | 52 Week High | $17.00 | |||
| Open | $22.90 | 52 Week Low | $3.55 | |||
| Day High | $23.29 | P/E | N/A | |||
| Day Low | $22.82 | EPS | $-1.33 | |||
| Volume | 2,795,449 | |||||
| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 1.35 -0.14 (9.4%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.49 | 52 Week High | $19.98 | |||
| Open | $1.48 | 52 Week Low | $10.52 | |||
| Day High | $1.50 | P/E | N/A | |||
| Day Low | $1.28 | EPS | $-1.45 | |||
| Volume | 3,261,713 | |||||
